Navigation Links
Media invitation: 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics
Date:9/15/2008

Journalists are invited to attend the 20th EORTCNCIAACR Symposium on "Molecular Targets and Cancer Therapeutics" in Geneva, Switzerland [Geneva Palexpo, Geneva] from Tuesday 21 October-Friday 24 October.

Today (Monday 15 September) is the deadline for booking accommodation via the official local agent if you wish to attend this symposium, organised jointly by the European Organisation for the Research and Treatment of Cancer, the US National Cancer Institute and the American Association for Cancer Research.

The symposium offers:

  • Cutting edge information on new cancer drug research and development from experts in Europe, North America, Asia and Australia;
  • Free registration for bona fide media with official press credentials (press card and/or a commissioning letter from the editor of the journal/website they represent);
  • All sessions open to journalists;
  • Media centre with free computing, fax, international phone, internet and photocopying facilities;
  • Two news briefings (12.15 hrs CEST: Wednesday 22 October and Thursday 23 October)

Topics at the news briefings or to be press released include:

  • Crossing the blood-brain barrier: scientists develop a new drug delivery system for hard-to-treat cancers of the central nervous system;
  • New "spindle poisoning" drug shows promise in phase I trial of solid tumours: phase II trials planned;
  • Scientists discover pattern of gene expression that predicts response to treatment in advanced colorectal cancer;
  • New drug shows impressive activity in patients with advanced disease, including medullary thyroid cancer. Phase III trials planned;
  • Researchers discover that a genetic mutation makes metastatic colorectal cancer patients resistant to anti-EGFR drugs. Potential for a biomarker to select patients who would respond to treatment;
  • Cancer vaccine show
    '/>"/>

Contact: Emma Mason
wordmason@mac.com
44-077-112-96986
ECCO-the European CanCer Organisation
Source:Eurekalert

0

GOOD

Page: 1 2

Related biology news :

1. September Geology and GSA Today media highlights
2. Heart of Herschel to be presented to media
3. Last chance for media to register for ECCO 14 -- the European Cancer Conference
4. October Geology and GSA Today media highlights
5. Media highlights in the November issues of Biophysical Journal
6. November GEOLOGY and GSA TODAY Media Highlights
7. Nanotechnology and the media: The inside story
8. December GEOLOGY and GSA TODAY media highlights
9. Better protection for biomedial devices could result from Rutgers-Camden research
10. Media highlights in the Dec. 15 issue of Biophysical Journal
11. Immediate action needed to save corals from climate change
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)Coral reef fish can undergo a personality change in warmer water, according to an intriguing new study suggesting that climate change may make some species more aggressive. , Experiments with two spe
(Date:12/3/2009)UPTON, NY A team of scientists from the U.S. Department of Energy,s (DOE) Brookhaven National Laboratory, Harvard University, and the Indian Institute of Science has made a major step in understandin
(Date:12/2/2009)PHILADELPHIA Cigarette smoking and alcohol consumption before head and neck cancer diagnosis strongly predicts the patient,s future risk of death, according to published studies. Now, results of a ne
Breaking Biology News(10 mins):Fish with attitude: Some like it hot 2Grooving down the helix 2Grooving down the helix 3Head and neck cancer survivors who use alcohol and cigarettes have increased death risk 2Hanger Orthopedic Group Inc Reports 240 31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 53000 1Hanger Orthopedic Group Inc Reports 240 31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 53000 2Hanger Orthopedic Group Inc Reports 240 31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 53000 3Hanger Orthopedic Group Inc Reports 240 31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 53000 4Hanger Orthopedic Group Inc Reports 240 31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 53000 5Hanger Orthopedic Group Inc Reports 240 31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 53000 6Hanger Orthopedic Group Inc Reports 240 31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 53000 7Hanger Orthopedic Group Inc Reports 240 31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 53000 8Hanger Orthopedic Group Inc Reports 240 31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 53000 9CareFusion Form 10 Registration Statement Declared Effective 52998 1CareFusion Form 10 Registration Statement Declared Effective 52998 2CareFusion Form 10 Registration Statement Declared Effective 52998 3CareFusion Form 10 Registration Statement Declared Effective 52998 4Cell Therapeutics Inc Announces Closing of Public Offering of Common Stock and Warrants 52996 1Cell Therapeutics Inc Announces Closing of Public Offering of Common Stock and Warrants 52996 2
...hange(TM) Software Access Local ...g. 13 BIO-key International,Inc. (OTC Bulletin Bo...utions and finger based biometric identification, ...ftware Module and its acceptance by several,agenci...This contract,represents BIO-key,s first with the ...
...on,Intelligence Corporation (OTC Bulletin Board: C...of electronic signature solutions for,business pro...recognized,leader in biometric signature verificat... three and six-month periods ended June 30, 2007. ...iod ended June 30,2007 increased 24% compared to $...
...o Equity, JERICHO, N.Y., Aug. 15 bioMETRX, Inc. ...d supplier of consumer,biometric products, today a... holders of its Series B common stock warrants tha... company by August 25, 2007. The Company notified...t,has elected to pay such holders $0.12 per share,...
Other Biology News:BIO-key(R) Announces Contracts for New Criminal Justice Data Sharing Solution 2BIO-key(R) Announces Contracts for New Criminal Justice Data Sharing Solution 3Communication Intelligence Corporation Reports Second Quarter 2007 Financial Results 2Communication Intelligence Corporation Reports Second Quarter 2007 Financial Results 3Communication Intelligence Corporation Reports Second Quarter 2007 Financial Results 4Communication Intelligence Corporation Reports Second Quarter 2007 Financial Results 5bioMETRX, Inc. Calls Series B Warrants 2
(Date:12/2/2009)SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans. ,
(Date:12/2/2009)NANJING, China, Dec. 2 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group,("Simcere" or the "Company") (NYSE: SCR ), a leading pharmaceutical company,specializing in the development, manufacturing, a
(Date:12/2/2009)SHANGHAI, Dec. 2 /PRNewswire-Asia/ -- The world is going through,extraordinary times; markets are in turmoil and uncertainty is part of many,businesses and industries. It turns out that the pharma ind
(Date:12/2/2009)HOBOKEN, N.J., Dec. 2 According to the National Institute of Health, 40 percent to 45 percent of Americans diagnosed with diabetes already have some stage of diabetic retinopathy. Diabetic retinopat
Breaking Biology Technology:S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 3Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 2Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 4
...wing a devastating legal rebuke, the chief executi... to pursue other business interests. , ,Jeff Cason...provider of uninterruptible power supply services,...es. Former executive vice president Charley Eaton ...was sued for copyright infringement by UPS manufac...
...part of a new contract with General Motors , the ...ill design plug-in batteries for a Saturn hybrid...hnson Controls-Saft Advanced Power Solutions will... recharged from a typical household electrical out...n recent months for JCS. In August of 2006, the Eu...
... a Wisconsin entrepreneur what,s vital to the succ...o get a shopping list as a definitive answer. Find...lth insurance, protecting intellectual property, a...replies. , ,Holding down taxes? That,s on the shor...er depends on the entrepreneur. Those who aren,t y...
Other Biology Technology:High taxes and low rates of entrepreneurship - is there a relationship? 2High taxes and low rates of entrepreneurship - is there a relationship? 3
...Description: Proteinase K is a highly active and s...ations purified from the fungus T. album. It cleav...up of N-substituted hydrophobic aliphatic and arom...e protease. Proteinase K is useful in purifying hi...
..., high throughput, water bath thermal cycler capab...oplates. This equates to 9,216 reactions per run w...y transfers a basket of plates between three water... are considerably faster than those of peltier blo...
...tidine Dideoxycytidine is a cytidine analog that ...viral activity. Immunogen: Chemical / Small Mol...ficity of the ddC antiserum was determined by calc...ddC analog at the 50% intercept of the respective ...
MSC.12 class II safety cabinet (Type A1) - CE Marked (230V / 50Hz) from Thermo Scientific
Biology Products: